Targeting DDR2 enhances tumor response to anti-PD-1 immunotherapy. [electronic resource]
Producer: 20200408Description: eaav2437 p. digitalISSN:- 2375-2548
- Animals
- CD8-Positive T-Lymphocytes -- immunology
- Cell Line, Tumor
- Dasatinib -- pharmacology
- Discoidin Domain Receptor 2 -- antagonists & inhibitors
- Drug Delivery Systems
- Female
- Immunity, Cellular
- Immunotherapy
- Mice
- Neoplasms, Experimental -- immunology
- Programmed Cell Death 1 Receptor -- antagonists & inhibitors
No physical items for this record
Publication Type: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.